There is a cardiovascular risk factor that is present at birth, determined entirely by genetics, and elevated in approximately one in five people. It is absent from standard lipid panels. It does not respond to most conventional therapies. And for a significant number of patients who present with premature or unexplained cardiovascular disease, it is the variable that explains what the routine cholesterol test could not.
That risk factor is lipoprotein(a). A lipoprotein A test is the only way to find it.
In this article, we’ll discuss:
What Is Lipoprotein(a)?
Lipoprotein(a) is a low-density lipoprotein particle with a unique structural addition: a glycoprotein called apolipoprotein(a), covalently bonded to the ApoB-100 component. This structural feature is what distinguishes Lp(a) from conventional LDL cholesterol and gives it distinct pathophysiological properties.
Clinically, Lp(a) is both atherogenic and prothrombotic. It promotes lipid deposition in the walls of blood vessels and inhibits fibrinolysis, increasing the tendency for blood clots to form in arteries. Standard LDL drives plaque accumulation. Lp(a) does that and impairs clot clearance simultaneously.
Why Genetics Determines the Result
Lp(a) levels are determined almost entirely by variation in the LPA gene and are established early in life. They are not meaningfully responsive to diet, exercise, or most conventional lipid therapies, including statins. This genetic determination has two important clinical implications: levels usually remain stable across a patient’s lifetime, and a single well-timed measurement is sufficient for risk stratification.
It also means there is no lifestyle intervention that will normalize an elevated result. The clinical response to a high Lp(a) is not to recommend dietary changes. It is to recalibrate the patient’s entire cardiovascular risk management strategy accordingly.
What does a lipoprotein A test tell you?
A lipoprotein A test tells you whether you carry an elevated level of a genetically determined cardiovascular risk factor that a standard cholesterol panel cannot detect. Specifically, it quantifies the concentration of Lp(a) particles in your blood and allows your physician to determine whether this independent risk factor is contributing to your overall risk of heart disease.
What Does a Blood Test for Lipoprotein A Measure?
A blood test for lipoprotein A quantifies the mass concentration of Lp(a) particles in plasma. Results are reported in milligrams per deciliter (mg/dL) or nanomoles per liter (nmol/L). These units are not interchangeable, and because different laboratories use different methodologies, understanding the reporting convention at the specific lab matters when comparing lipoprotein A test results across time or institutions.
The test is a simple blood draw. No fasting protocol is required, though individual laboratory instructions should be confirmed. What this test doesn’t measure is total cholesterol, LDL, HDL, or triglyceride levels. It is a targeted assay for a single particle class and should be ordered as such.
What an Lp(a) Test Does Not Replace
A lipoprotein A test is not a substitute for a comprehensive lipid panel. It is an addition to one. I order it alongside, not instead of, advanced lipid markers including ApoB, LDL particle number, and HDL functionality. The goal is to construct a complete atherogenic burden picture, not to replace one incomplete screen with another.
Who Should Get a Lipoprotein A Blood Test?
The National Lipid Association and the American Heart Association both support Lp(a) measurement in patients at elevated cardiovascular risk. In my practice, I recommend a lipoprotein A blood test for patients with any of the following:
Family history of early heart disease, including a first-degree relative with a history of early heart attack before age 55 in men or 65 in women
Personal history of cardiovascular disease, including a prior heart attack or stroke, particularly at a younger age than conventional risk models would predict
A confirmed or suspected diagnosis of familial hypercholesterolemia, given the high co-prevalence of elevated Lp(a) in that population
High LDL cholesterol that responds poorly to statin therapy, suggesting an additional atherogenic contributor
Heart or blood vessel disease without a clear conventional risk explanation
Patients requesting a complete cardiovascular baseline who want risk stratification beyond a standard lipid panel
I also include Lp(a) in the initial evaluation for patients enrolled in our cardiovascular risk assessment program, regardless of whether their standard numbers have raised concern. The absence of conventional risk factors is not the same as the absence of risk.
Lipoprotein A Test Results and Normal Range
The clinically accepted reference thresholds, as applied by the National Lipid Association, are:
Desirable: Below 30 mg/dL (approximately below 75 nmol/L)
Borderline elevated: 30 to 50 mg/dL
High: Above 50 mg/dL (approximately above 125 nmol/L)
For most patients, levels below 30 mg/dL are considered desirable and usually do not require medication specifically for Lp(a). At the high end, particularly above 90 mg/dL or 200 nmol/L, the cardiovascular risk elevation is substantial and warrants aggressive management of all other modifiable risk factors.
Many people with high Lp(a) have no awareness of it. Their routine cholesterol test results appear unremarkable. Their physician has never ordered the specific assay that would reveal it. This is a correctable gap.
How I Interpret Lipoprotein A Test Results Clinically
Elevated Lp(a) is an independent risk factor for coronary heart disease, stroke, aortic valve stenosis, and peripheral blood vessel disease. The relationship is continuous: higher levels carry higher risk, and that risk is additive to whatever LDL-mediated risk is already present.
I do not interpret lipoprotein A test results in isolation. Context is everything. A patient with high Lp(a) but low LDL, no hypertension, no inflammatory burden, and no family health history is a different clinical picture from a patient with high Lp(a) and an already elevated cardiovascular risk profile. The number informs the conversation. It does not replace it.
Test results may also have implications for first-degree family members. Because Lp(a) is genetically determined, elevated results in one patient should prompt a conversation about cascade screening for siblings and adult children.
What is the normal range for a lipoprotein A test?
The accepted clinical thresholds are below 30 mg/dL (desirable), 30 to 50 mg/dL (borderline elevated), and above 50 mg/dL (high risk). Results may also be reported in nmol/L, where less than 75 nmol/L is desirable and above 125 nmol/L is high.
Why a Routine Cholesterol Test Misses This
A routine cholesterol test measures total cholesterol, LDL, high-density lipoprotein, and triglyceride levels. It is a foundational screen and a reasonable starting point. It was not designed to capture the full spectrum of atherogenic risk.
A standard cholesterol test that only measures LDL as a composite value cannot separate conventional LDL particles from the Lp(a) fraction. Even if your LDL appears controlled on therapy, your Lp(a)-driven risk remains entirely unaccounted for. For patients with familial hypercholesterolemia in particular, this is a clinically significant blind spot, given the high co-prevalence of elevated Lp(a) in that population.
Why the Testing Gap Has Persisted
The absence of Lp(a) from standard screening reflects the historical absence of approved, targeted therapies. The Food and Drug Administration has not yet approved a pharmacological agent specifically indicated for Lp(a) lowering. Without a clear intervention, the clinical incentive to measure was lower.
That reasoning is changing. RNA-targeted therapies that suppress hepatic Lp(a) production have demonstrated substantial reductions in Phase 2 and Phase 3 trials. The evidentiary case for routine Lp(a) screening is strengthening. And even in advance of approved therapies, identifying high Lp(a) changes how I manage every other modifiable cardiovascular risk factor in that patient’s care.
Managing Elevated Lp(a): What the Evidence Supports
Because Lp(a) itself is largely unresponsive to conventional interventions, the clinical strategy focuses on reducing total cardiovascular risk through every other available pathway. In practice, that means:
Driving LDL cholesterol to lower targets than standard guidelines would require for that patient’s baseline risk, to offset the additional atherogenic load
Rigorous management of high blood pressure, dysglycemia, and systemic inflammation
Advanced lipid evaluation, including ApoB to fully characterize particle burden
Coronary artery calcium scoring to quantify existing arterial disease and guide therapy intensity
Optimization of all lifestyle variables that modulate heart and blood vessel disease risk
For a small number of patients with very high Lp(a) and established or recurrent cardiovascular disease, lipoprotein apheresis is an evidence-based therapeutic option. This procedure removes Lp(a) directly from the blood and is currently reserved for the highest-risk patients with progressive disease despite optimal medical therapy. It is not a first-line intervention, but it is an established one within that specific clinical context.
The Emerging Pharmacological Landscape
This is an area of active and rapid clinical investigation. Small interfering RNA agents targeting the LPA gene have demonstrated Lp(a) reductions of 80 to 90 percent in early-phase trials. These therapies are not yet approved for routine clinical use as of this writing. However, late-stage trial results are anticipated, and the treatment options available to patients with high Lp(a) are expected to expand meaningfully over the next several years.
For patients identified today, establishing a documented baseline and building an ongoing care relationship with a physician who is tracking this space is the most clinically sound approach available.
What happens if lipoprotein A is high?
Elevated Lp(a) independently increases the risk of coronary heart disease, heart attack, stroke, aortic valve stenosis, and peripheral artery disease — regardless of LDL level. It produces no symptoms. The clinical response is to intensify management of every other modifiable cardiovascular risk factor.
How We Approach Lp(a) Testing at Elite Medical Associates
At Elite Medical Associates, a lipoprotein A blood test is one component of a structured, physician-directed cardiovascular evaluation. I do not order tests in isolation. Every test I order is ordered because it will change or refine how I manage that patient’s care. Generating a data point without a clinical plan for what to do with it is not precision medicine.
Our cardiovascular evaluation integrates advanced lipid markers, inflammatory biomarkers, metabolic parameters, and imaging-based arterial assessment, where clinically indicated. The goal is not a longer lab report. It is a more accurate picture of individual risk, interpreted by a physician who has the time and the clinical framework to act on it.
What to Expect When You Have a Blood Test for Lipoprotein A with Us
When a patient presents for Lp(a) evaluation, I begin with a complete clinical history: family health history, prior cardiovascular events, existing lipid data, and a full inventory of modifiable risk factors. The blood draw is straightforward. The interpretation is where the clinical judgment lies.
Lipoprotein A test results are reviewed in the context of the patient’s complete cardiovascular profile. I do not communicate a number without context, and I do not discharge a patient with an abnormal result without a clear explanation of what it means, what it does not mean, and what, if anything, changes in their care plan as a result.
If you have a family history of early heart disease, a personal history of cardiovascular disease, or want a complete cardiovascular baseline that goes beyond routine screening, contact us today.